IMPACT OF RITUXIMAB ON SYNOVIAL GENE EXPRESSION

doi:10.1136/annrheumdis-2013-203219.18

Yasser M El-Sherbiny, Sarah Churchman, Paul Emery, Edward M Vital, Frederique Ponchel. Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, St James’s University Hospital, Beckett Street, Leeds, UK

Introduction Quality and duration of rituximab therapy response in rheumatoid arthritis have not been totally explained. In the synovium, three studies have indicated a relationship between higher plasma cell numbers at baseline and worse, or shorter lasting responses [1–5]. In this study we measured synovial expression of genes involved in B-cell biology, cell survival, cell trafficking and inflammation.

Methodology Synovial arthroscopic biopsies were collected and snap frozen from patients at baseline and 26 weeks after rituximab. Immunohistochemistry was performed for CD3, CD19, CD20cy, CD138 and CD68 and scored for positive cells/mm² using digital image analysis. The remainder of the tissue was used for RNA extraction. A 48 gene custom Taqman array was designed, including genes for cell lineage markers (CD19, CD20, CD3, CD138 & CD68), BAFF-APRIL system, immunoglobulins, cytokines, chemokines and adhesion molecules or cell trafficking. Informative data are available from 32 biopsies pre-Rituximab treatment and 23 post-treatment. Unsupervised clustering was performed to all gene expression to all from 32 biopsies pre-Rituximab treatment and 23 post-treatment. BAFF (all p < 0.05). Comparing EULAR responders and non-responders, there were trends to higher baseline CD20 gene expression in non-responders (p = 0.079) and greater reduction in CXCL13 (p = 0.066) and MMP (p = 0.024) in responders.

Lower expression of ICAM (p = 0.021), FGF (p = 0.044), CD20 (p = 0.055) and p53 (p = 0.025) and higher expression of APRIL (p = 0.029) at baseline was associated with normalisation of CRP after therapy. Furthermore, these patients also showed a significantly greater reduction in expression of CD4, CD55, CD68, CXCL12, EGF, FGE, ICAM, PECAM, STAT5, TGF-beta, APRIL and BAFF (all p < 0.05).

Conclusions Results point to key differences in synovial gene expression in patients with clinical response to rituximab, obviously in relation with genes involved in cell trafficking and survival.

References

A5.19 IN AFRICAN PATIENTS WITH RHEUMATOID ARTHRITIS ACPA RECOGNISE CITRULLINATED FIBRINOGEN AND THE IMMUNODOMINANT EPITOPES BORNE BY THE FIBRIN PEPTIDES α36–50 AND β60–74, LIKE IN CAUCASIANS


1^l L Nogueira, 1M Comillet, 1M Singwe-Ngandeu, 1S Viatte, 1^l S Bas, 1C Gabay, 1^l G Séité, 2Laboratory of Epidemiology and Rheumatoid Autoimmunity, UMR CNRS 5165, INSERM U 1056, Toulouse III University; 2Laboratory of Cell Biology and Cytology, University Hospital of Toulouse; Toulouse, France; 2Unit of Rheumatology, School of Medicine, University of Yaoundé, Cameroon; 2Arthritis Research, UK Epidemiology Unit, University of Manchester; 2Division of Rheumatology; University Hospitals of Geneva; 2Department of Genetics and Laboratory Medicine; 2Department of Pathology & Immunology; University of Geneva, School of Medicine, Genève, Suisse

Background and Objectives Although most studies concerning the Rheumatoid Arthritis (RA)-specific antibodies to citrullinated proteins (ACPA) have been performed in populations of Caucasian ancestry, anti-CCP2 antibodies were demonstrated to be also good markers for RA in African patients. In one cohort from Cameroon, frequency of the HLA-DRB1 shared epitope (SE) alleles, although higher in RA patients than in controls, was lower than in Caucasian patients. Furthermore, known Caucasian non-HLA susceptibility genes did not confer the same risk in Africans.

The purposes of the present study were, first, to analyse in African patients with RA the autoantibodies to citrullinated human fibrinogen (AhFibA), then, to investigate to what extent the two citrullinated fibrin peptides α36–50 and β60–74, which bear the immunodominant epitopes, were recognised by the sera of these patients.

Methods AhFibA and autoantibodies to α36–50 and β60–74 were measured by ELISA in the serum of 56 consecutive RA patients with established disease from the Rheumatology unit of Yaoundé, Cameroon. 101 patients with other rheumatic diseases or healthy individuals were used as controls.

Results Using the 95%-specificity thresholds previously defined with a French cohort, 73% of the RA sera from African patients were positive for AhFibA versus 83% in French patients. The anti-β60–74 and anti-α36–50 autoantibodies were detected in 41/56 (73%) and 25/56 (45%) African RA sera versus 71% and 51% in French RA patients, respectively. Moreover, 38/41 (93%) of the AhFibA-positive sera recognised either α36–50 and/or β60–74, as previously observed in French patients. Finally, the mean AhFibA (OD = 1.32) and anti-β60–74 (OD = 1.32) titers were significantly higher in patients with at least one copy of the HLA-DRB1 SE (17/56, 30%) than in those without SE (OD = 0.64 and 0.60, respectively; p = 0.005 and p < 0.02), while the titer of anti-α36–50 autoantibodies did not differ.

Conclusions AhFibA are markers for RA also in African patients. In these patients, autoantibodies to α36–50 and β60–74 peptides are present in proportions similar to those found in Caucasians. Like in Caucasians, they account for almost all the reactivity to fibrinogen. HLA-DRB1 SE alleles, although less common among African RA patients, are associated with higher titres of AhFibA and of autoantibodies to β60–74, suggesting that SE alleles partly control the AhFibA production, besides still unknown factors. This study shows that even in different genetic backgrounds the ACPA response is a hallmark of RA, and strongly suggests that its fine specificity to citrullinated fibrin is identical in Caucasians and Africans.
**Results** First, we observed that up-regulation of costimulatory molecules CD86, CD80 and CD40 induced by BCR cross-linking was down-regulated after IVIg incubation and was associated with a massive reduction of tyrosine phosphorylation. Low mobilisation of intracellular Calcium, which is a hallmark of anergy, was also observed in IVIg-treated B cells. Next, we observed that following BCR stimulation, IVIg blocks BCR aggregation within lipid rafts and increases its internalisation. Consequently, BCR stimulation is not achievable and results in a low activation of the PI3K-Akt signalling pathway. Finally, we demonstrated that IVIg down-regulates NFkB activation and promotes NFAT transcription factors entry in the nucleus. These findings demonstrated that IVIg induces a selective transcriptional programme, allowing nuclear signals to be independently activated, leading to alternative B cell fates.

**Conclusions** Our data suggest that IVIg could induce B cells to adopt a state that results in a functional silencing, also called anergy. Our findings provide insights into the effectiveness of IVIg in treating pathologies associated with the loss of B cell tolerance. We also describe a new model to explore the complexity of positive versus negative selection in human B cells.

A5.21 LACK OF IL-27 SIGNALING LEADS TO AN INTRINSIC B CELL DEFECT AND PROTECTION AGAINST CIA

doi:10.1136/annrheumdis-2013-203219.21

1Odília BJ Corneth, 1Patrick S Asmaowieda, 1Laurens P Kil, 1Anne-Marie C Mus, 1Franka Luk, 1Sandra MJ Paulissen, 1Rudi W Hendriks, 1Erik Lubberts. 1Departments of Rheumatology, 1Immunology, 1Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

**Introduction** The IL-27 receptor (IL-27R) is expressed on naïve T helper cells. Signaling induces Th1 differentiation and IL-10 production and inhibits Th17 differentiation. In addition, the IL-27R is also expressed on B cells, where it is linked to B cell proliferation and IgG2a class switch recombination. However, its role is not fully understood. We therefore aim to determine the role of IL-27R signalling on B cells, both in T cell independent and in T cell dependent immune responses.

**Methods** To determine the effect of IL-27 on B cells, we isolated naïve B cells from wild type mice and cultured them in the absence or presence of rIL-27. T cell dependent responses were investigated using the collagen induced arthritis (CIA) model in wild type and IL-27R deficient (WSX-1 deficient) mice. T cell independent B cell responses were investigated using the TNF-Ficoll immunisation model.

**Results** Naïve wild type B cells cultured in the presence of rIL-27 showed increased proliferation and expression of activation markers. Next, we investigated the role of IL-27R signalling in vivo in CIA. Both the incidence and severity of CIA were significantly lower in IL-27R deficient mice. Splenic germinal centre B cells were decreased in these mice. In addition, both auto-reactive IgM and IgG2a antibody levels were significantly decreased. These data suggest an impairment of B cell immunity in IL-27R deficient mice. However, CIA also depends on T cells. To determine whether the impairment of B cell immunity in IL-27R deficient mice was B cell intrinsic, we used the T cell independent TNF-Ficolli Immunisation model. Wild type and IL-27R deficient mice were immunised with TNF-Ficolli i.p. and sacrificed seven days later. IL-27R deficient mice had fewer splenic IgM and IgG3 plasma cells and lower serum TNF specific IgM and IgG3 antibody levels.

**Conclusions** Here we show that IL-27R signalling on B cells is essential for proliferation and activation of B cells. Impaired B cell immunity in IL-27R deficient mice is caused by an intrinsic B cell defect, leading to impaired plasma cell formation and antibody production in both T cell independent as well as T cell dependent immune responses.

A5.22 MEMBRANE-BOUND AND SOLUBLE BAFF EXPRESSION BY HUMAN RHEUMATOID FIBROBLAST-LIKE SYNOVIOCYTES IN RESPONSE TO TLR STIMULATION


1NW Kam, 2A Filer, 2C Buckley, 1MBombardieri, 2C Pittazilis. 1William Harvey Research Institute, Queen Mary University of London, London, UK; 2Division of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, UK

**Background and Objectives** Cell activating factors of TNF family (BAFF) is associated with the survival and maturation of B cells. BAFF is widely expressed in the rheumatoid arthritis (RA) synovium which is characterised by the presence of synovial niches of autoreactive B cells and sustain in situ autoantibody production. Importantly, B cell niches remain functional in the RA-SCID model in the absence of recirculating cells, suggesting that autocrine mechanisms support ongoing B cell activation in the RA synovium. BAFF exerts its functional role both as a membrane bound protein and in soluble form. Here we investigated whether resident stromal cells in the RA synovium, synovial fibroblasts (RASF), are capable of producing either forms of BAFF and thus contribute to local B cell activation.

**Methods** mRNA BAFF in RASF stimulated with TLR2, TLR3 and TLR4 ligands was assessed by quantitative Taqman PCR RA dermal fibroblasts (RAFD) and osteoarthritis SF (OASF) were used as controls. The cytoplasmic, membrane bound and/or soluble forms of BAFF were investigated by 1) Western blot using total and membrane-enriched protein extracts, 2) flow cytometry, 3) ELISA and 4) immunocytochemistry.

**Results** In vitro stimulation of TLR3, and to a significantly lesser extent TLR4, but not TLR2 on RASF led to strong induction of BAFF mRNA. In response to TLR3, soluble BAFF was time-dependently released in the supernatant of RASF (~600 pg/ml) and, to a lesser extent, OASF and RADE RASF constitutively expressed both cytoplasmic and membrane bound BAFF as demonstrated by WB, FACS and immunocytochemistry which was upregulated upon TLR3 stimulation and was significantly increased as compared to RADE.

**Conclusions** Here we provide conclusive evidence that SF in the RA synovium are a pivotal source of the B cell survival factor BAFF at both mRNA and protein level. In addition to their significant constitutive expression, RASF can further up-regulate cytoplasmic, membrane-bound and soluble BAFF in response to TLR3 stimulation. Overall, our data strongly support a fundamental role for RASF in sustaining functional B cell activation and cytokine production in the inflamed RA synovium.

A5.23 MULTIPARAMETER PHOSPHO-FLOW ANALYSIS OF B CELLS FROM PATIENTS WITH RHEUMATOID ARTHRITIS

doi:10.1136/annrheumdis-2013-203219.23

1Daniel Szil, 1Judit Pozsgay, 2Zsu zsanna Banko, 1Tamas Gati, 2Bernadett Rojkovich, 1Gabriella Saraym. 1Department of Immunology, 2Division of Immunity and Infection, Semmelweis University, Budapest, Hungary

**Background and Objectives** Rheumatoid arthritis (RA) is a common, relapsing autoimmune disease, which affects approximately 1% of the population worldwide. While the specific molecular events that lead to initiation and onset of RA are not known, an uncontrolled activation of the immune system is considered to be a critical component of the disease. B lymphocytes undoubtedly play a critical role in disease aetiology. Antigen binding to B-cell receptor (BCR) triggers B cell activation, although the threshold of activation can be influenced by other receptors, such as TLR9. TLR9 has received substantial attention as a pathogenic co-stimulator of